Skip to main content
Premium Trial:

Request an Annual Quote

CLC Bio, Isilon to Bundle Software and Storage

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – CLC Bio and Isilon Systems have partnered to offer their high-throughput sequencing analysis and storage products to life sciences customers, CLC Bio said today.

The firms plan to start the partnership by offering a bundled solution that combines the CLC Genomics Machine with Isilon IQ's NAS (network-attached storage) platform for genomics researchers. The companies also plan to offer customized setups for large scale solutions.

"With high-throughput sequencing rising in popularity tremendously fast, our consumers are constantly faced with storage challenges of a scale they haven't experienced previously," CLC Bio CEO Thomas Knudsen said in a statement.

"Getting the sequencing instruments working and producing large datasets is the first hurdle in a high-throughput sequencing workflow," Leonard Iventosch, Isilon's VP of global channel and OEM, said in a statement. "We know from our customers that analyses and storage are the other major hurdles."

The Scan

Long COVID-19 Susceptibility Clues Contained in Blood Plasma Proteome

A longitudinal study in eBioMedicine found weeks-long blood plasma proteome shifts after SARS-CoV-2 infection, along with proteomic signatures that appeared to coincide with long Covid risk.

Tibetan Study Finds Adaptive Variant Influencing Skin Pigmentation

With a combination of phenotyping and genetic data, researchers document at PNAS a Tibetan-enriched enhancer variant influencing melanin synthesis and ultraviolet light response.

Domestication Linked to Nervous System Genes in Inbred Mouse Strains

Researchers highlighted more than 300 positively selected genes in domesticated mice, including genes linked to nervous system function or behavior in Genome Biology.

ALS Genetic Testing May Be Informative Across Age Ranges, Study Finds

Researchers in the journal Brain identified clinically actionable variants in a significant subset of older ALS patients, prompting them to point to the potential benefits of broader test use.